Vanguard Asset Management’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Vanguard Asset Management's SMMT Position: Q3 2026 in Review
Vanguard Asset Management increased its Summit Therapeutics (SMMT) stake by 354% in Q3 2026, buying an estimated $1.51M and bringing the position to 129,787 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1514.
Vanguard Asset Management first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. 296 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Vanguard Asset Management held 129,787 shares of Summit Therapeutics worth $2.19M as of Q3 2026.
- Vanguard Asset Management bought 101,176 Summit Therapeutics shares in Q3 2026, an estimated $1.51M.
- Summit Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1514 holding.
- Vanguard Asset Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 296 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.